Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724543 | 0.93 | MAOA (0.57) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5022652 | 0.85 | CYP19A1 (0.47) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5016468 | 0.85 | CYP19A1 (0.47) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL8169795 | 0.82 | PDE4B (0.43) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL2556718 | 0.81 | CYP17A1 (0.39) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL2559970 | 0.81 | IDO1 (0.39) | KDM4EALDH1A1LMNACYP17A1CYP19A1 | |
| SCHEMBL5022822 | 0.80 | MAPT (0.48) | NPC1KDM4EALDH1A1LMNARAB9A | |
| SCHEMBL5018006 | 0.79 | CYP19A1 (0.49) | MAOAKDM4ELMNACYP19A1CYP11B1 | |
| SCHEMBL2562674 | 0.79 | MAOA (0.35) | MAOANPC1KDM4EALDH1A1LMNA | |
| SCHEMBL5016548 | 0.78 | CYP19A1 (0.51) | KDM4EALDH1A1LMNACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492568-B2 | Chromane derivatives as TRPV3 modulators | Glenmark Pharamceuticals S.A. (CH) | 2013-07-23 | — | — | US | disclosed |
| EP-2074106-B1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LAB LTD (IN) | 2013-04-17 | — | — | EP | disclosed |
| EP-2225205-B1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2013-01-02 | — | — | EP | disclosed |
| US-8263648-B2 | Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 | Mylan Laboratories Ltd. (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2011132051-A2 | TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-7968724-B2 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20110098316-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2225205-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| WO-2009077068-A9 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMA SPA (IT) | 2009-08-20 | — | — | WO | disclosed |
| EP-2074106-A1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | Matrix Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009077068-A1 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070913-A1 | Ester derivatives as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008032171-A1 | DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MATRIX LABORATORIES LTD. (DE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1554262-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals Limited (IN) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | MAOA 977/4885NPC1 853/4885KDM4E 4205/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | MAOA 977/4885NPC1 853/4885KDM4E 4205/4885 |
| US-20110098316-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | MAOA 2613/4885NPC1 816/4885KDM4E 3467/4885 |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | PDE4A, PDE4B, PDE12 | MAOA 148/4885NPC1 4500/4885KDM4E 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.